BioSurfaces has received a $2.06m one-year grant from the Bill & Melinda Gates Foundation to further the development of its Bio-Spun Cell Chamber (BSCC) device.
The device encapsulates cells that are modified genetically to produce therapeutic proteins to provide long-term delivery of biotherapeutic agents for chronic illness treatment.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
With the new funding, BioSurfaces plans to increase the BSCC device cell capacity.
BioSurfaces’ pre-clinical research suggests that the device could meet the three critical objectives for implantable cell therapy delivery devices, including nutrient absorption for cells, immune system protection, and biotherapeutic agent release into the body.
Furthermore, the company expects the research funded by the grant to demonstrate the BSCC as a compact, minimally invasive therapy option. This is especially beneficial for patient compliance in developing countries where supply chain and economic access issues often lead to inconsistent treatment.
The device’s features include ease of loading and implantation, an internal barrier to prevent cellular migration without the need for immunosuppression, minimal fibrotic response, and various sizes and configurations.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBioSurfaces is set to collaborate with external research teams to obtain genetically engineered cells for a specific disease.
The successful development of the device’s technology could significantly enhance patient outcomes for a range of long-term conditions such as liver disease, diabetes, and various rare and infectious diseases.
BioSurfaces CEO and president Matthew Phaneuf said: “Receiving this prestigious grant from the Gates Foundation represents a significant step forward in our goal to provide a practical, long-term therapeutic delivery solution for patients, especially for those in underserved areas.
“Our Bio-Spun Cell Chamber device is specifically engineered to address the challenges of fibrosis and immune rejection while enabling long-term biotherapeutic delivery. This device could be extremely helpful in low- and middle-income countries where access to biotherapeutics may be limited.”
